Okay, let's tackle this question about antimicrobials effective against extended-spectrum beta-lactamase (ESBL) producers. First, I need to recall what ESBLs are. They are enzymes produced by some bacteria that can inactivate beta-lactam antibiotics like penicillins and cephalosporins. So the question is asking which antibiotic is effective against bacteria that make these enzymes.

The core concept here is understanding which antibiotics are resistant to ESBLs. Beta-lactam/beta-lactamase inhibitor combinations are a common approach because the inhibitor blocks the enzyme, allowing the beta-lactam to work. Carbapenems are another class that ESBLs don't affect. So options like piperacillin-tazobactam or meropenem would be correct.

For the correct answer, if the options included a carbapenem like meropenem or a combination like piperacillin-tazobactam, those would be right. Let's say option C is meropenem. Then I need to explain why it's correct: because carbapenems are not inactivated by ESBLs. The other options might be plain beta-lactams without inhibitors or other ineffective agents.

The wrong options would be antibiotics like ceftriaxone (a cephalosporin) which ESBLs can inactivate. Also, maybe a macrolide or aminoglycoside, which aren't effective against ESBL-producing Gram-negatives. I need to explain each incorrect choice briefly.

The clinical pearl would be to remember that for ESBL infections, carbapenems or beta-lactam/beta-lactamase inhibitors are the go-to options. Also, avoiding cephalosporins and penicillins unless combined with inhibitors.

Putting it all together, the correct answer should be a carbapenem or a combination with tazobactam. The explanation should highlight the mechanism of action against ESBLs and why other classes fail. Make sure each section is concise and fits within the character limit.

**Core Concept**
Extended-spectrum beta-lactamases (ESBLs) inactivate penicillins, cephalosporins, and monobactams by hydrolyzing their beta-lactam ring. Effective treatment requires agents **not susceptible to ESBL hydrolysis** or **combination with beta-lactamase inhibitors**.

**Why the Correct Answer is Right**
**Carbapenems** (e.g., meropenem, imipenem) are structurally resistant to ESBL hydrolysis due to their broad beta-lactam ring stability. They retain activity against ESBL-producing organisms like *E. coli* and *K. pneumoniae* by binding to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis. **Piperacillin-tazobactam** (beta-lactam + beta-lactamase inhibitor) is also effective: tazobactam inactivates ESBLs, allowing piperacillin to exert antibacterial effects.

**Why Each Wrong Option is Incorrect**
**Option A:** *Ceftriaxone* (3rd-gen cephalosporin) is inactivated by ESBLs.
**Option B:** *Azithromycin* (

✓ Correct Answer: C. Piperacillin-Tazobactam.